Skip to main content
Clinical Trials/NCT06097026
NCT06097026
Recruiting
Not Applicable

Role of Inhaled Nitric Oxide in Vascular Mechanics and Right Ventricular Function Following Cardiac Surgery

Fernando Suarez Sipmann1 site in 1 country54 target enrollmentNovember 22, 2023

Overview

Phase
Not Applicable
Intervention
Nitric Oxide
Conditions
Collapsed Lung
Sponsor
Fernando Suarez Sipmann
Enrollment
54
Locations
1
Primary Endpoint
Right ventricular cardiac function specifically those directly related to the estimation ofright ventricular-vascular coupling
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to evaluate the role of nitric oxide on pulmonary vasculature and right ventricular function in postoperative cardiac surgery patients.

Detailed Description

This study will evaluate modifiable pathophysiological treatments for postoperative pulmonary hypertension and right ventricular dysfunction. One pharmacological, inhaled nitric oxide, and one non-pharmacological, the OLA strategy combining lung recruitment and stabilization with individually optimized positive end-expiratory pressure (PEEP) and the possible synergistic effects of both interventions on right ventricular performance. Apart from acting specifically on the pathophysiological mechanisms described, the combination of an OLA strategy and iNO may be particularly beneficial, as modification of pulmonary status by OLA may, in theory, enhance the effects of iNO by significantly increasing gas exchange area and thus alveolar ventilation. A number of closely related physiological variables will also be studied to better characterize the effects of both strategies and their combination. This may help to better establish the indication for iNO in cardiac surgery patients and improve our understanding of mechanisms that are also present in ARDS patients, albeit on a different scale. This is a prospective randomized controlled physiological prospective study to be performed in two hospitals. The intervention period is limited to the first 2 -3 hours postoperatively. A total of 54 patients will be recruited.

Registry
clinicaltrials.gov
Start Date
November 22, 2023
End Date
December 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fernando Suarez Sipmann
Responsible Party
Sponsor Investigator
Principal Investigator

Fernando Suarez Sipmann

MD PhD Intesive Care Medicine, Principal Investigator

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

iNO 20-40 ppm

In this arm, inhaled nitric oxide therapy will be initiated at 20 ppm immediately after randomization and after initial data collection. The dose will be reassessed after the first 30 min and may be increased to a maximum of 40 ppm depending on the response observed in ventricular function.

Intervention: Nitric Oxide

iNO 20 - 40 ppm + Lung recruitment (iNO-RM)

After 30 min after initiation of nitric oxide therapy following randomization, once patient stability has been confirmed, a brief recruitment maneuver will be performed and the subsequent PEEP level will be individualized according to the best lung compliance. Ventilation will then continue with the standard baseline ventilator settings, but with the PEEP level individually optimized.

Intervention: Alveolar recruitment maneuver

iNO 20 - 40 ppm + Lung recruitment (iNO-RM)

After 30 min after initiation of nitric oxide therapy following randomization, once patient stability has been confirmed, a brief recruitment maneuver will be performed and the subsequent PEEP level will be individualized according to the best lung compliance. Ventilation will then continue with the standard baseline ventilator settings, but with the PEEP level individually optimized.

Intervention: Nitric Oxide

Outcomes

Primary Outcomes

Right ventricular cardiac function specifically those directly related to the estimation ofright ventricular-vascular coupling

Time Frame: A first TTE baseline measurement (T1) will be taken after arrival in the ICU after cardiac surgery, then another measurement will be taken 30 minutes after the first intervention (at iNO) (T2), and a new measurement will be taken 30 minutes later (T3).

The parameters will be evaluated by TEE. Right ventricular function parameters will be assessed by the ratio of right ventricular end-diastolic to left ventricular end-diastolic diameters, right ventricular shortening fraction, tricuspid annular plane systolic excursion (TAPSE), myocardial performance index (MPI). estimation of systolic pulmonary artery pressure (PAPs), estimation of pulmonary vascular resistance by Doppler, Right ventricular outflow tract notch pattern, right ventricular outflow tract acceleration time (RVOT-AT).

Secondary Outcomes

  • Electrical impedance tomography (EIT) derived variables(A first baseline measurement (T1) will be taken after arrival at the ICU after cardiac surgery, then another measurement will be taken 30 minutes after the first intervention (in iNO) (T2), and a new measurement will be taken 30 minutes later (T3).)

Study Sites (1)

Loading locations...

Similar Trials